Plain-English translation of NCT07052565 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing a new treatment called ECAR01, which uses your own immune cells that have been specially modified in a laboratory to fight autoimmune diseases. The treatment is designed for people with conditions like rheumatoid arthritis, lupus, Sjögren's syndrome, or systemic sclerosis that haven't improved with standard medicines. Researchers will give you different doses of the medication to see which works best and is safest.
Many people with autoimmune diseases don't get better even after trying multiple standard treatments. This trial explores whether engineering immune cells to target specific disease-causing cells might offer a new hope for patients who haven't responded to conventional medicines.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn so doctors can remove and modify your immune cells in the laboratory. Before the treatment, you'll receive chemotherapy medication to prepare your body. Then on day zero, you'll receive an infusion of your enhanced immune cells back into your body. The study will track your health closely after that to monitor for side effects and to see whether the treatment helps your autoimmune disease improve. The trial enrolls about 18 people total across three different dose levels.
AI-generated summary from trial data · Jun 5, 2026 · Not medical advice
China
Sponsor
Anhui Provincial Hospital
Enrollment target
~18 participants
Started
July 2025
Primary completion
November 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in July 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
chen zhu, M.D
Anhui Provincial Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.